ImmunityBio Investors Urged to Act Before May 2026 Securities Class Action Deadline Investors of ImmunityBio are reminded about the upcoming deadline for a class action lawsuit on May 26, 2026, regarding potential financial claims.

ImmunityBio Investors Urged to Act Before May 2026 Securities Class Action Deadline #United_States #New_York #Faruqi_&_Faruqi #ImmunityBio #IBRX

Investors in ImmunityBio Have a Chance to Lead a Significant Class Action Lawsuit Rosen Law Firm has initiated a class action lawsuit on behalf of ImmunityBio investors. Affected shareholders may be eligible for compensation. Act before the deadline!

Investors in ImmunityBio Have a Chance to Lead a Significant Class Action Lawsuit #USA #New_York #Rosen_Law_Firm #ImmunityBio #IBRX

Class Action Alert: ImmunityBio Inc. Investors Can Lead Major Lawsuit Investors of ImmunityBio, Inc. facing significant losses have a valuable opportunity to become the lead plaintiff in a class action lawsuit against the company.

Class Action Alert: ImmunityBio Inc. Investors Can Lead Major Lawsuit #USA #San_Diego #Class_Action #ImmunityBio #IBRX

Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against ImmunityBio, Inc. and Its Directors Investors in ImmunityBio, Inc. are urged to contact Pomerantz LLP regarding potential claims of securities fraud and unlawful practices.

Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against ImmunityBio, Inc. and Its Directors #United_States #New_York #Pomerantz #ImmunityBio #IBRX

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MO 11.1x
2. #LOVE 7.2x
3. #GFS 5.7x
4. #CHWY 4.8x
5. #IBRX 4.5x

#OptionFlow #OptionsTrading #Trading

💥 Institutions trading #options with high urgency! PM Top Sweep Activity from 🔥 INSIDERFINANCE.CO

💥 Institutions trading #options with high urgency!

PM Top Sweep Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NVDA 102.7K
2. #TSLA 79.3K
3. #AAL 36.7K
4. #MU 31.7K
5. #IBRX 30.8K

#OptionFlow #OptionsTrading #Trading

📈 Heavy institution #Equity #optionsvolume! AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥 1

📈 Heavy institution #Equity #optionsvolume!

AM Top Equity Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #TSLA 60.0K
2. #NVDA 51.4K
3. #IBRX 34.8K
4. #AAL 22.2K
5. #MARA 18.8K

#OptionFlow #OptionsTrading #Trading

💥 Institutions trading #options with high urgency! AM Top Sweep Activity from 🔥 INSIDERFINANCE.CO

💥 Institutions trading #options with high urgency!

AM Top Sweep Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #TSLA 57.6K
2. #NVDA 42.9K
3. #IBRX 29.8K
4. #AAL 22.2K
5. #MARA 18.8K

#OptionFlow #OptionsTrading #Trading

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors ImmunityBio (NASDAQ: IBRX) announced regulatory approval in Macau SAR, China for ANKTIVA (nogapendekin alfa inbakicept-pmln) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary tumors.The authorization used a reliance-based review referencing prior FDA and EMA decisions, marks ANKTIVA’s first approval in Asia, and supports the company’s ongoing global expansion across 34 countries and territories. The company cited QUILT 3.032 data published in NEJM Evidence and The Journal of Urology demonstrating durable responses.

#IBRX ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

www.stocktitan.net/news/IBRX/immunity-bio-a...

Stocks Under $10 to Watch in 2026: IBRX, VTIX, NDRA, SMX — Emerging Themes Across Biotech, XR, Diagnostics, and AI Supply Chains Getting your Trinity Audio player ready... As capital rotation intensifies across micro- and small-cap equities in 2026, a new wave of sub-$10 stocks is gaining traction among investors seeking exposu...

Stocks Under $10 to Watch in 2026: #IBRX, #VTIX, #NDRA, #SMX — Emerging Themes Across Biotech, XR, Diagnostics, and AI Supply Chains

thestreetreports.com/stocks-under...

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors ImmunityBio (NASDAQ: IBRX) reported successful validation of large‑scale manufacturing and cryo‑banking for autologous memory cytokine‑enhanced NK (M‑ceNK) cells.Key metrics: single apheresis yields up to 5×10⁹ NK cells, providing 8–10 doses; finished doses available within 12 days; programs enrolled 74 subjects with manufacturing datasets from 64 apheresis collections. Phase 1 (QUILT‑3.076) combined M‑ceNK with ANKTIVA® in 10 patients with no Grade 4/5 TRAEs reported. Cryopreserved M‑ceNK retained tumor cytotoxicity across multiple histologies.

#IBRX ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

www.stocktitan.net/news/IBRX/immunity-bio-a...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PATH, #ISPR, #IBRX, #TSSI, #APLD

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#LUNR, #CVNA, #IBRX, #PATH, #APLD

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AXTI, #VRT, #CRML, #IBRX, #APLD

#OptionFlow #OptionsTrading #Trading

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 ImmunityBio (NASDAQ: IBRX) will host a live conference call at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, March 3, 2026 to provide a business update and review financial results for the year ended December 31, 2025.According to the company, the call will cover progress across its clinical trial pipeline. Interested parties can join via the investor relations website or by phone; a replay will be posted and available for at least 90 days.

#IBRX ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

www.stocktitan.net/news/IBRX/immunity-bio-t...

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ ImmunityBio (NASDAQ: IBRX) completed enrollment in the randomized QUILT 2.005 trial with 366 BCG-naïve NMIBC CIS patients, randomized to ANKTIVA plus BCG or BCG alone. An FDA-requested interim analysis showed improved duration of complete response for ANKTIVA plus BCG (9-month CR 84% vs 52%, p=0.0455) with no new safety signals. The company plans to submit a BLA by Q4 2026 and continues a recombinant BCG Expanded Access Program with 580 patients enrolled.

#IBRX ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

www.stocktitan.net/news/IBRX/immunity-bio-c...

Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% | The Motley Fool On Feb. 23, 2026, investors weighed ANKTIVA’s explosive revenue ramp against ImmunityBio’s deep losses and ambitious global expansion.

#IBRX #a7b73cf4-8f1d-496f-bef5-3feb8dc3af31 #coveragestock-market-today #Health #Care

Origin | Interest | Match

📢 Stocks Trending NOW: #NVO #LLY #VNDA #NOVO-B.CO #DPZ #ACLX #IBRX #GOSS #D #TIRX

Pomerantz Law Firm Launches Investigation into ImmunityBio, Inc. for Potential Securities Fraud Pomerantz Law Firm is probing potential securities fraud involving ImmunityBio, Inc. (IBRX) following significant stock price decline after clinical results announcement.

Pomerantz Law Firm Launches Investigation into ImmunityBio, Inc. for Potential Securities Fraud #United_States #New_York #Pomerantz #ImmunityBio #IBRX

📢 Stocks Trending NOW: #WMT #CVNA #FIG #LMND #DE #KLAR #DASH #IBRX #XYZ #HIMS

BREAKING NEWS: ( NASDAQ: #IBRX ) Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

Breaking News: ( NASDAQ: #IBRX ) Why ImmunityBio Stock Is Soaring Today

Pomerantz Law Firm Investigates Potential Securities Fraud at ImmunityBio, Inc. Amidst Recent Stock Drop Pomerantz LLP is probing potential claims against ImmunityBio, Inc. following a significant stock drop related to clinical trial results. Investors may have legal options.

Pomerantz Law Firm Investigates Potential Securities Fraud at ImmunityBio, Inc. Amidst Recent Stock Drop #USA #New_York #Pomerantz_LLP #ImmunityBio #IBRX

Investor Alert: Pomerantz Law Firm Investigates ImmunityBio on Behalf of Investors Following Recent Press Release Pomerantz LLP is probing potential securities fraud claims against ImmunityBio, Inc. after recent press release about clinical trials led to share price drop.

Investor Alert: Pomerantz Law Firm Investigates ImmunityBio on Behalf of Investors Following Recent Press Release #USA #New_York #Pomerantz_LLP #ImmunityBio #IBRX

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy ImmunityBio (NASDAQ: IBRX) reported updated Phase 2 QUILT-3.078 data in recurrent or progressive glioblastoma as of January 22, 2026. Of 23 enrolled patients, 19 remain alive and median overall survival is not yet reached; four deaths reported. In the 14-patient evaluable cohort (median follow-up 6 months), the longest survival from recurrence reached 12 months and ongoing. Baseline mean absolute lymphocyte count (ALC) was ~0.9 x10^3/µL; mean ALC rose to ≥ 1.4 x10^3/µL within one cycle (p<0.001, N=14) and remained significantly increased through 20 weeks (p≤0.026). The regimen showed a manageable safety profile: 3 treatment-related serious adverse events reported and no CRS or ICANS. Randomized 1L and 2L+ trials are in development.

#IBRX ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

www.stocktitan.net/news/IBRX/immunity-bio-r...

Today’s most trending tickers with positive sentiment (last 24h):

#TSLA: 29
#ASTS: 28
#INTC: 28
#SPY: 24
#NFLX: 16
#META: 13
#AAPL: 13
#CAPT: 11
#COF: 11
#AMZN: 11
#ASTI: 10
#SNDK: 10
#GME: 10
#NAMM: 10
#LMND: 9
#IOBT: 8
#IBRX: 8
#BABA: 8

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #UUUU 51% OTM
2. #AXTI 38% OTM
3. #BKSY 37% OTM
4. #NUAI 36% OTM
5. #IBRX 36% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AXTI, #BKSY, #IBRX, #HIMS, #SOFI

#OptionFlow #OptionsTrading #Trading

Today’s most trending tickers with positive sentiment (last 24h):

#NFLX: 59
#SPY: 26
#INTC: 21
#ASTS: 19
#TSLA: 13
#PAVM: 12
#SNDK: 12
#AAPL: 12
#MU: 10
#JPM: 10
#CAPT: 8
#NVDA: 7
#IBRX: 7
#TACO: 7
#JP: 7
#AMZN: 7
#GME: 7
#JNJ: 6

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GOOGL, #PYPL, #BIDU, #IBRX, #MSFT

#OptionFlow #OptionsTrading #Trading